BR112021010909A2 - Compostos para o tratamento de infecção por arenavírus - Google Patents

Compostos para o tratamento de infecção por arenavírus Download PDF

Info

Publication number
BR112021010909A2
BR112021010909A2 BR112021010909-9A BR112021010909A BR112021010909A2 BR 112021010909 A2 BR112021010909 A2 BR 112021010909A2 BR 112021010909 A BR112021010909 A BR 112021010909A BR 112021010909 A2 BR112021010909 A2 BR 112021010909A2
Authority
BR
Brazil
Prior art keywords
compound
independently selected
alkyl
fact
compounds
Prior art date
Application number
BR112021010909-9A
Other languages
English (en)
Portuguese (pt)
Inventor
Eric Brown
Vidyasagar Reddy Gantla
Nadezda Sokolova
Michael Bruno Plewe
Gregory Henkel
Kenneth McCormack
Original Assignee
Arisan Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arisan Therapeutics, Inc. filed Critical Arisan Therapeutics, Inc.
Publication of BR112021010909A2 publication Critical patent/BR112021010909A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41921,2,3-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D249/18Benzotriazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BR112021010909-9A 2018-12-06 2019-12-03 Compostos para o tratamento de infecção por arenavírus BR112021010909A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862776390P 2018-12-06 2018-12-06
US62/776,390 2018-12-06
PCT/US2019/064223 WO2020117794A1 (en) 2018-12-06 2019-12-03 Compounds for the treatment of arenavirus infection

Publications (1)

Publication Number Publication Date
BR112021010909A2 true BR112021010909A2 (pt) 2021-08-24

Family

ID=70975517

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021010909-9A BR112021010909A2 (pt) 2018-12-06 2019-12-03 Compostos para o tratamento de infecção por arenavírus

Country Status (10)

Country Link
EP (1) EP3890731A4 (https=)
JP (1) JP7675009B2 (https=)
KR (1) KR20210106997A (https=)
CN (1) CN113329750B (https=)
AR (1) AR117228A1 (https=)
AU (1) AU2019393784B2 (https=)
BR (1) BR112021010909A2 (https=)
EA (1) EA202191001A1 (https=)
MX (2) MX2021005234A (https=)
WO (1) WO2020117794A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116217490B (zh) * 2023-02-03 2025-09-26 中国人民解放军军事科学院军事医学研究院 一种苯并咪唑类化合物及其制备方法和应用
EP4434972A1 (en) * 2023-03-22 2024-09-25 Eberhard-Karls-Universität Tübingen Atm kinase inhibitors
WO2025137345A1 (en) * 2023-12-20 2025-06-26 Arisan Therapeutics Inc. Crystalline forms of an imidazopyridine derivative

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2293638T3 (es) * 1994-03-25 2008-03-16 Isotechnika, Inc. Mejora de la eficacia de farmacos por deuteracion.
WO2012065297A1 (en) * 2010-11-16 2012-05-24 Impact Therapeutics, Inc. 3-ARYL-6-ARYL-[1,2,4]TRIAZOLO[4,3-a]PYRIDINES AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF
AP3675A (en) * 2012-02-17 2016-04-15 Kineta Four Llc Antiviral drugs for treatment of arenavirus infection
US9688680B2 (en) 2014-08-04 2017-06-27 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
US11352328B2 (en) 2016-07-12 2022-06-07 Arisan Therapeutics Inc. Heterocyclic compounds for the treatment of arenavirus

Also Published As

Publication number Publication date
EP3890731A4 (en) 2022-08-17
MX2021005234A (es) 2021-08-11
AU2019393784B2 (en) 2025-06-12
JP2022509763A (ja) 2022-01-24
MX2024013042A (es) 2024-12-06
CA3118765A1 (en) 2020-06-11
EA202191001A1 (ru) 2021-08-16
CN113329750B (zh) 2025-10-17
AU2019393784A1 (en) 2021-05-27
EP3890731A1 (en) 2021-10-13
JP7675009B2 (ja) 2025-05-12
WO2020117794A1 (en) 2020-06-11
CN113329750A (zh) 2021-08-31
KR20210106997A (ko) 2021-08-31
AR117228A1 (es) 2021-07-21

Similar Documents

Publication Publication Date Title
US11352328B2 (en) Heterocyclic compounds for the treatment of arenavirus
US11548893B2 (en) Enantiomerically pure adamantane carboxamides for the treatment of filovirus infection
US12240857B2 (en) Adamantane derivatives for the treatment of filovirus infection
AU2021253796B2 (en) Compounds and methods for the treatment of COVID-19
AU2018331172B2 (en) Influenza virus replication inhibitor and use thereof
Pan et al. Development of benzimidazole derivatives to inhibit HIV-1 replication through protecting APOBEC3G protein
CA3189027A1 (en) Antiviral heteroaryl ketone derivatives
TW202214604A (zh) 含腈之抗病毒化合物類
US12358897B2 (en) Compounds and method of treating COVID-19
BR112021010909A2 (pt) Compostos para o tratamento de infecção por arenavírus
ES2938335T3 (es) Nuevo derivado de pirrolopiridina, método para producir el mismo y uso del mismo
JP2018532786A (ja) テトラヒドロインダゾール及びその医学的使用
US12419865B2 (en) Compounds for the treatment of arenavirus infection
CA3118765C (en) Compounds for the treatment of arenavirus infection
WO2021262426A9 (en) Adamantane amides and thioamides for the treatment of ebolavirus infection
OA20266A (https=)
EA044865B1 (ru) Соединения для лечения аренавирусной инфекции

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]